Acute coronary syndrome
Acute coronary syndrome is the name for a group of sudden heart problems that come from a fall in blood flow to the heart muscle. The group covers unstable angina and the two kinds of heart attack that doctors tell apart by the ST segment of the heart tracing: STEMI, with a raised ST segment, and NSTEMI, without one. MeSH describes it as an episode of reduced blood flow that lasts longer than a brief bout of angina and may end in a heart attack.
Also called ACS
- Condition
- In this atlas
Overview
Technical summary
MeSH D054058, last updated 2015-06-01. The grouping of three conditions rests on the first sentence of the abstract of one open-access paper (PMC11904130, a small hospital risk-factor study); it is used for that definition only and is not a guideline. The MeSH scope note gives the description of a longer episode that may end in a heart attack. The US prescribing label of a P2Y12 inhibitor names the term in its first indication. MedlinePlus has no page of its own on the term; its heart attack page links to a page on it by another organization, which was not read.
Burden
No burden claims are published.
Claims and evidence
No claims are published for this condition yet.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact Evaluated for this: Clopidogrel
Applies to Recipient not specified People for whom the US label of clopidogrel (Plavix) lists an indication: acute coronary syndrome, acute ST-elevation myocardial infarction managed medically, recent myocardial infarction, recent stroke, established peripheral arterial disease
Population, setting and follow-up
- Patients described in the indications section of the label. The label passages read do not state an age range.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Not stated in the label passages read
- Gestational age Not reported
- Postnatal age Not reported
The US label of Plavix (clopidogrel), in the Sanofi-Aventis U.S. LLC version dated 2025-05-30 in openFDA, lists the medicine to reduce the rate of myocardial infarction and stroke in patients with acute coronary syndrome without ST-segment elevation (unstable angina or non-ST-elevation myocardial infarction), in patients with acute ST-elevation myocardial infarction who are to be managed medically, and in patients with established peripheral arterial disease or a history of recent myocardial infarction or recent stroke. The label carries a boxed warning titled diminished antiplatelet effect in patients with two loss-of-function alleles of the CYP2C19 gene.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Only the indications, the title of the boxed warning and the mechanism sentence were read; contraindications, doses, interactions and other warnings were not recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact Evaluated for this: Prasugrel
Applies to Recipient not specified People for whom the US label of prasugrel (Effient) lists an indication: acute coronary syndrome managed with percutaneous coronary intervention
Population, setting and follow-up
- Patients described in the indications section of the label. The label passages read do not state an age range.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Not stated in the label passages read
- Gestational age Not reported
- Postnatal age Not reported
The US label of Effient (prasugrel), in the Cosette Pharmaceuticals, Inc. version dated 2022-09-07 in openFDA, lists the medicine to reduce the rate of thrombotic cardiovascular events, including stent thrombosis, in patients with acute coronary syndrome who are to be managed with percutaneous coronary intervention (PCI): patients with unstable angina or non-ST-elevation myocardial infarction, and patients with ST-elevation myocardial infarction managed with primary or delayed PCI. The label carries a boxed warning that the medicine can cause significant, sometimes fatal, bleeding.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Only the indications, the first line of the boxed warning and the mechanism sentence were read; the rest of the boxed warning, contraindications, doses, interactions and other warnings were not recorded. Labels change, and openFDA's version may be older than the current label. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact Evaluated for this: Ticagrelor
Applies to Adult People for whom the US label of ticagrelor (Brilinta) lists an indication: acute coronary syndrome or past heart attack, high-risk coronary artery disease, acute ischemic stroke or high-risk transient ischemic attack
Population, setting and follow-up
- Patients described in the indications section of the label. The label does not state an age range in the passages read.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Not stated in the label passages read
The US label of BRILINTA (ticagrelor), in the AstraZeneca version dated 7 May 2026 in openFDA, lists the medicine for lowering the chance of cardiovascular death, myocardial infarction and stroke in patients with acute coronary syndrome or a history of myocardial infarction. It also lists it for lowering the chance of a first myocardial infarction or stroke in patients with coronary artery disease at high risk for such events, and for lowering the chance of stroke in patients with acute ischemic stroke (NIH Stroke Scale score of 5 or less) or a high-risk transient ischemic attack. The label carries a boxed warning that, like other antiplatelet agents, the medicine can cause significant, sometimes fatal bleeding.Limitations. This claim records what the label says it is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Only the indications and the first line of the boxed warning were read; contraindications, doses, interactions and other warnings were not recorded. Labels change: openFDA also lists repackager copies with older text. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Registry records
Assembled by a program from ClinicalTrials.gov. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry trials 284
Record details
- Record id
cardio:acute-coronary-syndrome- Content hash
5824f445df46e129bfeac32ee7ab70fe9cbbb8b6692ece23cf0dcb1813005dbe